Analyzing...
Loading company...
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,167 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹9,646 Cr revenue.
COGS 29.3%, employees 22.4%.
“Also, you mentioned like you should see 150 basis point expansion in EBITDA margin.”
“So overall the company growth is around 10% to 11%. That is what is the overall broadly.”
“EBITDA margin improvement in spite of lower growth in the quarter, we have almost around 2.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 14.1%▲ | 10.3% |
| ROCE | 16.4%▲ | 13.7% |
| Net Margin | 11.6%▲ | 7.6% |
| EBITDA Margin | 21.0%▲ | 15.4% |
| Debt To Equity | 0.09x▼ | 0.15x |
| Rev Growth 3yr | 15.5%▲ | 10.0% |
| EPS Growth 3yr | 34.3%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9,646 Cr +7.9% | ₹8,940 Cr +16.0% | ₹7,705 Cr +23.4% | ₹6,244 Cr +7.1% | ₹5,830 Cr +7.6% | ₹5,420 Cr +16.6% | ₹4,649 Cr +23.2% | ₹3,773 Cr |
| Other Income | ₹174 Cr +88.0% | ₹93 Cr -25.6% | ₹125 Cr -0.7% | ₹126 Cr +88.7% | ₹67 Cr +5.9% | ₹63 Cr -6.2% | ₹67 Cr +16.2% | ₹58 Cr |
| Total Income | ₹9,821 Cr +8.7% | ₹9,032 Cr +15.4% | ₹7,830 Cr +22.9% | ₹6,370 Cr +8.0% | ₹5,896 Cr +7.5% | ₹5,483 Cr +16.3% | ₹4,716 Cr +23.1% | ₹3,831 Cr |
| COGS | ₹2,823 Cr +1.6% | ₹2,779 Cr +7.9% | ₹2,576 Cr +11.7% | ₹2,307 Cr +14.5% | ₹2,015 Cr +16.6% | ₹1,728 Cr +5.1% | ₹1,644 Cr +32.6% | ₹1,240 Cr |
| ₹8,162 Cr +6.1% | ₹7,696 Cr +11.9% | ₹6,879 Cr +22.3% | ₹5,625 Cr +18.1% | ₹4,761 Cr +16.3% | ₹4,094 Cr +3.1% | ₹3,969 Cr +20.9% | ₹3,283 Cr | |
| Profit Before Tax | ₹1,573 Cr +39.0% | ₹1,131 Cr +34.2% | ₹843 Cr +13.1% | ₹745 Cr -34.4% | ₹1,136 Cr -18.2% | ₹1,389 Cr +86.0% | ₹747 Cr +36.2% | ₹548 Cr |
| Exceptional Items | (₹86 Cr) +57.8% | (₹205 Cr) -90.3% | (₹108 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹381 Cr +10.9% | ₹344 Cr +9.6% | ₹313 Cr +23.7% | ₹253 Cr +13.0% | ₹224 Cr -6.6% | ₹240 Cr +77.4% | ₹135 Cr +29.8% | ₹104 Cr | |
| Net Profit | ₹1,184 Cr +50.8% | ₹785 Cr +50.2% | ₹523 Cr +9.2% | ₹479 Cr -46.2% | ₹890 Cr -22.0% | ₹1,141 Cr +89.1% | ₹604 Cr +36.5% | ₹442 Cr |
| Profit (Owners) | ₹1,141 Cr +54.7% | ₹738 Cr +34.8% | ₹547 Cr +16.1% | ₹471 Cr -46.7% | ₹884 Cr -22.4% | ₹1,140 Cr +88.0% | ₹606 Cr +36.3% | ₹445 Cr |
| Minority Interest | ₹43 Cr -10.3% | ₹48 Cr ↑ Recovery | (₹24 Cr) ↓ Decline | ₹8 Cr +34.3% | ₹6 Cr +405.3% | ₹1 Cr ↑ Recovery | (₹3 Cr) -5.7% | (₹3 Cr) |
| Other Comprehensive Income | ₹43 Cr ↑ Recovery | (₹25 Cr) -159.8% | (₹9 Cr) ↓ Decline | ₹7 Cr +144.7% | ₹3 Cr ↑ Recovery | (₹0.40 Cr) ↓ Decline | ₹4 Cr ↑ Recovery | (₹4 Cr) |
| EPS | ₹44.98 | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 | ₹44.93 | ₹23.99 | ₹17.60 |
| Diluted Shares | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr |
| Profit Or Loss Of Associates | (₹8 Cr) -231.4% | (₹2 Cr) +63.6% | (₹6 Cr) +51.4% | (₹13 Cr) +38.8% | (₹21 Cr) -174.8% | (₹8 Cr) +1.4% | (₹8 Cr) -331.5% | (₹2 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
IPCA Laboratories Limited has informed the Exchange regarding ''.Intimation to non-email cases regarding weblink of Annual Report'
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 07-Aug-2026.
IPCA Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 13, 2026
IPCA Laboratories Limited has informed the Exchange regarding 'Business Responsibility and & Sustainability Report'.
IPCA Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
IPCA Laboratories Limited has informed the Exchange about Credit Rating
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange about Transcript
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange regarding 'Revised Link for q4FY26 Conference Call to be held today'.
IPCA Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 6 per equity share.
IPCA Laboratories Limited has informed the Exchange regarding re-appointment of Mr Mr. Prashant Godha as Executive Director of the company w.e.f. August 16, 2026.
IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
IPCA Laboratories Limited has informed the Exchange about Schedule of meet